Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer
Future Oncology · 2024
DOI: 10.2217/fon-2023-0763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Cengiz Karacin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Peritoneal Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Aim
To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded.
Results
The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8).
Conclusion
Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
- Depatment of Medical Oncology, Losante Children & Adult Hospital, Ankara, Turkey.
- Departmen of Medical Oncology, Dicle University, Diyarbakir, Turkey.
- Department of Medical Oncology, Atatürk University Training Hospital, Erzurum, Turkey.
- Department of Medical Oncology, Kartal Training & Research Hospital, Istanbul, Turkey.
- Department of Medical Oncology, Osmangazi University, Eskisehir, Turkey.
ORCID-Profile: Cengiz Karacin, Zuhat Urakci, Deniz Can Guven, Mutlu Dogan, Yakup Ergun
Zitieren
APA
Karacin, C., Sunar, V., Urakci, Z., Yilmaz, A., Ayhan, M., Ersoy, M., Guven, D. C., Erturk, I., Durmus, Y., Karacin, P., Boran, N., Ustun, Y. E., Meydan, M., Dogan, M., Oksuzoğlu, B., Ates, O., Karaca, M., Uncu, D., Ergun, Y., & Arik, Z. (2024). Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0763
Vancouver
Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, et al. Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. 2024. doi:10.2217/fon-2023-0763
BibTeX
@article{Karacin2024,
author = {Karacin, Cengiz and Sunar, Veli and Urakci, Zuhat and Yilmaz, Ali and Ayhan, Murat and Ersoy, Mustafa and Guven, Deniz Can and Erturk, Ismail and Durmus, Yasin and Karacin, Pinar and Boran, Nurettin and Ustun, Yaprak Engin and Meydan, Mutlu and Dogan, Mutlu and Oksuzoğlu, Berna and Ates, Ozturk and Karaca, Mustafa and Uncu, Dogan and Ergun, Yakup and Arik, Zafer},
title = {Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0763}
}
EUVIMED